"Moving to Slide 26. Also, Kymriah\u00ae had an excellent year with sales up 68%, driven by strong double-digit growth across all geographies despite pandemic conditions. We continue to expand our global presence with now over 290 centers qualified to administer Kymriah\u00ae across 27 markets. Commercial manufacturing for Kymriah\u00ae has been expanded with the recent approval of FBRI in Japan, and this is building on previous approvals of Stein and Les Ulis earlier in the year. In 2020, we made also significant progress in expanding our global manufacturing capacity with a 70% increase compared to previous year. And we also continue to improve the robustness of our process, leading to an increased manufacturing success rate."